Life Sciences Supply Chain Disruptions Likely to Persist through 2022

Supply chain disruption will be with biopharmaceutical companies for the foreseeable future, according to the recent CFO survey, Supply Chain Resilience, by BDO. A separate report by Catalent, Allogeneic and Autologous Cell Therapies Report 2022, agrees, saying, “Bottlenecks are one of the most common hurdles facing cell and gene therapy developers.”